Spots Global Cancer Trial Database for catumaxomab
Every month we try and update this database with for catumaxomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | NCT00464893 | Gastric Cancer Gastric Adenoca... | Catumaxomab catumaxomab | 18 Years - | Neovii Biotech | |
| Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | NCT01246440 | Ovarian Cancer | Catumaxomab | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites | NCT01065246 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers | NCT00822809 | Cancer Neoplasms Carcinoma Malignant Ascit... | Catumaxomab Prednisolone | 18 Years - | Neovii Biotech | |
| Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | NCT01815528 | Recurrent Epith... | Catumaxomab | 18 Years - | Charite University, Berlin, Germany | |
| Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites | NCT01065246 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | NCT01815528 | Recurrent Epith... | Catumaxomab | 18 Years - | Charite University, Berlin, Germany | |
| Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | NCT04799847 | Bladder Cancer | Catumaxomab | 18 Years - | LintonPharm Co.,Ltd. | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech | |
| Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas | NCT01504256 | Gastric Adenoca... Siewert Type II... Siewert Type II... | catumaxomab, Fl... Fluorouracil, l... | 18 Years - | AIO-Studien-gGmbH | |
| Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | NCT00563836 | Ovarian Cancer Epithelial Ovar... | Catumaxomab | 18 Years - | Neovii Biotech | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients | NCT01320020 | Epithelial Canc... | catumaxomab | 18 Years - | Neovii Biotech | |
| Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer | NCT00563836 | Ovarian Cancer Epithelial Ovar... | Catumaxomab | 18 Years - | Neovii Biotech | |
| Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites | NCT00326885 | Malignant Ascit... | catumaxomab | 18 Years - | Neovii Biotech | |
| A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients | NCT01320020 | Epithelial Canc... | catumaxomab | 18 Years - | Neovii Biotech | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission | NCT01246440 | Ovarian Cancer | Catumaxomab | 18 Years - | Grupo Español de Investigación en Cáncer de Ovario | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
